Industry Newspolygenic embryo screeningivfnucleus genomicsethical implications
Reproductive Firms Promote Polygenic Embryo Screening
6.1
Nucleus Genomics recently ran provocative New York City ads claiming polygenic embryo screening can predict traits such as height and intelligence, drawing public and expert scrutiny. Experts say PES, used only with IVF (about 2% of U.S. births) and costing roughly $2,500 per screened embryo, remains unproven since the first PES birth in 2020, raising accuracy, equity, and regulatory concerns.
Key Points
- 1Highlight provocative ad campaign by Nucleus Genomics promoting polygenic embryo screening for traits.
- 2Warn about PES technical limits from biased GWAS samples, pleiotropy, and uncertain long-term predictive power.
- 3Advise clinicians and policymakers to limit use, demand validation, and address inequity and regulatory gaps.
Scoring Rationale
Emerging commercialization and ethical risks drive relevance; limited novelty and unproven scientific validation lower overall impact.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
